Table 3.
Radiological, laboratory, and treatment characteristics.
| n = 81 (percentage) | |
|---|---|
| Syndesmophytes (radiograph/MR/CT) | 42/57 (73.68%) |
| Radiographic erosions | 65/76 (85.52%) |
| Radiological sacroiliitis | 80/81 (98.76%) |
| Positive RF | 73/79 (92.40%) |
| Citrullinated peptide antibodies | 16/18 (88.88%) |
| Positive HLA B-27 | 60/67 (89.55%) |
| Treatment | |
| NSAIDs | 28/47 (59.57%) |
| Corticosteroids | 39/47 (82.97%) |
| Gold salts | 12/47 (25.53%) |
| Hydroxychloroquine | 9/47 (19.14%) |
| Sulfasalazine | 9/47 (19.14%) |
| Methotrexate | 15/47 (31.91%) |
| Leflunomide | 4/47 (8.51%) |
| TNF-α-i | 5/47 (10.63%) |
| Others | 6/47 (12.76%) |
CT: computerized tomography; MR: magnetic resonance, NSAIDs: nonsteroidal anti-inflammatory drugs; RF: rheumatoid factor; TNF-i: tumor necrosis factor inhibitor.